Beta-blockers in the treatment of hypertension: new data, new directions.
Weber
Michael A
MA
State University of New York, Downstate Medical College, 450 Clarkson Avenue, Brooklyn, NY 11023, USA. michaelwebermd@cs.com
Bakris
George L
GL
Giles
Thomas D
TD
Messerli
Franz H
FH
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000368:Aged; D001578:Benzopyrans / Q000009:adverse effects / Q000627:therapeutic use; D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000401:mortality / Q000517:prevention & control; D000077261:Carvedilol; D002423:Cause of Death; D004983:Ethanolamines / Q000009:adverse effects / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D000068577:Nebivolol; D017410:Practice Guidelines as Topic; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D001578:Benzopyrans; D002227:Carbazoles; D004983:Ethanolamines; D011412:Propanolamines; D014665:Vasodilator Agents; D000068577:Nebivolol; D000077261:Carvedilol